Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients

Renal Failure

Volumn 27, Issue 2, 2005, Pages 163-169

  Zanos, S ^a   Mitsopoulos, E ^a   Sakellariou, G ^a  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Calcium channel blockers; Hemodialysis; Lipids; Parathyroid hormone

Indexed keywords

ALBUMIN; CALCIUM CHANNEL BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CALCIUM CELL LEVEL; CHOLESTEROL BLOOD LEVEL; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EVALUATION; FEMALE; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UREMIA;

AGED; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 15344340709     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-200048229     Document Type: Article

References (22)

1. Attman, P.O.; Samuelsson, O.; Alaupovic, P. Lipoprotein metabolism and renal failure. Am. J. Kidney Dis. 1993, 21, 573-592.
2. DeFronzo, R.A.; Andres, R.K.; Edgar, P.; Walker, W.G. Carbohydrate metabolism in uremia. A review. Medicine 1972, 52, 469-481.
3. Massry, S.G. Insulin secretion in uremia. Am. J. Kidney Dis. 2001, 38 (suppl. 1), S58-S62.
4. Hager, S.R. Insulin resistance of uremia. Am. J. Kidney Dis. 1989, 14, 272-276.
5. Fadda, G.Z.; Akmal, M.; Premdas, F.; Lipson, L.G.; Massry, S.G. Insulin release from pancreatic islets: effect of CRF and excess PTH. Kidney Int. 1988, 33, 1066-1072.
6. Akmal, M.; Kassim, S.E.; Soliman, A.R.; Massry,S.G. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990, 37, 854-858.
7. Bro, S.; Olgaard, K. Effects of excess PTH on nonclassical target organs. Am. J. Kidney Dis. 1997, 30, 606-620.
8. Chiu, K.C.; Chuang, L.M.; Lee, N.P.; Ryu, J.M.; McGullam, J.L.; Tsai, G.P.; Saad, M.F. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism 2000, 49, 1501-1505.
9. Thanakitcharu, P.; Fadda, G.Z.; Hajj, S.M.; Massry, S.G. The mechanism of the protective effect of verapamil in pancreatic islets of CRF rats. Endocrinology 1991, 729, 1749-1754.
10. Gadallah, M.F.; El-Shahawy, M.; Andrews, G.; Ibrahim, M.; Ramdeen, G.; Hanna, D.; Gorospe, W.; Morkos, A.; Abbassian, M.; Moles, K. Factors modulating cytosolic calcium: role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients. Adv. Perit. Dial. 2001, 17, 29-36.
11. Zanos, S.P.; Mitsopoulos, E.; Papadopoulou, D.; Sakellariou, G. Changes in lipid profiles during the first 6 months of dialysis and factors influencing them, Proceedings of the ASN/ISN World Congress of Nephrology, San Francisco, CA, Oct. 13-17, 2001, Abstract No. A2167.
12. Fadda, G.Z.; Thanakitcharu, P.; Smogorzewski, M.; Massry, S.G. Parathyroid hormone raises cytosolic calcium in pancreatic islets: study on mechanisms. Kidney Int. 1993, 43, 554-560.
13. Hajjar, S.M.; Fadda, G.Z.; Thanakitcharu, P.; Smogorzewski, M.; Massry, S.G. Reduced activity of Na(+)-K(+) ATPase of pancreatic islets in chronic renal failure: role of secondary hyperparathyroidism. J. Am. Soc. Nephrol. 1992, 2, 1355-1359.
14. Akmal, M.; Massry, S.G.; Goldstein, D.A.; Fand, P.; Weisz, A.; DeFronzo, R.A. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J. Clin. Invest. 1985, 75, 1037-1044.
15. Stein, P.P.; Hunt, W.A.; Johnson, C.M. Insulin resistance in uremia: an in vivo and in vitro study. Metabolism 1989, 38, 562-567.
16. Liang, K.; Oveisi, F.; Vaziri, N.D. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int. 1998, 53, 626-630.
17. Akmal, M.; Perkins, S.; Kasim, S.E.; Oh, H.Y.; Smogorzewski, M.; Massry, S.G. Verapamil prevents chronic renal failure-induced abnormalities in lipid metabolism. Am. J. Kidney Dis. 1993, 22, 158-163.
18. Lim, P.S.; Hung, T.S.; Yeh, C.H.; Yu, M.H. Effects of treatment of secondary hyperparathyroidism on the lipid profile in patients on hemodialysis. Blood Purif. 1998, 16, 22-29.
19. Mak, R.H. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998, 53, 1353-1357.
20. Khajehdehi, P.; Taheri, S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J. Renal Nutr. 2003, 13, 78-83.
21. Lacour, B.; Roullet, J.B.; Liagre, A.M.; Jorgetti, V.; Beyne, P.; Dubost, C.; Drucke, T. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am. J. Kidney Dis. 1986, 8, 422-429.
22. Navarro, J.F.; Teruel, J.L.; Lasuncion, M.A.; Mora-Fernandez, C.; Ortuno, J. Relationship between serum parathyroid hormone levels and lipid profile in hemodialysis patients. Evolution of lipid parameters after parathyroidectomy. Clin. Nephrol. 1998, 49, 303-307.